21 October 2024
21 October 2024
A partial clinical hold was placed on the registrational trial after results showed variance between squamous and non-squamous NSCLC patient responses.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report assesses the current landscape of microbiome-based therapeutics in the seven major markets. Recent advancements in microbiome research along with recent approvals of microbiome-based therapies, such as Ferring Therapeutics’ Rebyota and Seres Therapeutics’ Vowst, are expected to further accelerate the integration of microbiome treatments into clinical settings. By harnessing knowledge derived from the expanding research, the microbiome has the potential to offer new avenues for personalized medicine and targeted interventions.
GlobalData's latest report assesses the current landscape of microbiome-based therapeutics in the seven major markets. Recent advancements in microbiome research along with recent approvals of microbiome-based therapies, such as Ferring Therapeutics’ Rebyota and Seres Therapeutics’ Vowst, are expected to further accelerate the integration of microbiome treatments into clinical settings. By harnessing knowledge derived from the expanding research, the microbiome has the potential to offer new avenues for personalized medicine and targeted interventions.
GlobalData's latest report assesses the current landscape of microbiome-based therapeutics in the seven major markets. Recent advancements in microbiome research along with recent approvals of microbiome-based therapies, such as Ferring Therapeutics’ Rebyota and Seres Therapeutics’ Vowst, are expected to further accelerate the integration of microbiome treatments into clinical settings. By harnessing knowledge derived from the expanding research, the microbiome has the potential to offer new avenues for personalized medicine and targeted interventions.
GlobalData's latest report assesses the current landscape of microbiome-based therapeutics in the seven major markets. Recent advancements in microbiome research along with recent approvals of microbiome-based therapies, such as Ferring Therapeutics’ Rebyota and Seres Therapeutics’ Vowst, are expected to further accelerate the integration of microbiome treatments into clinical settings. By harnessing knowledge derived from the expanding research, the microbiome has the potential to offer new avenues for personalized medicine and targeted interventions.
GlobalData's latest report assesses the current landscape of microbiome-based therapeutics in the seven major markets. Recent advancements in microbiome research along with recent approvals of microbiome-based therapies, such as Ferring Therapeutics’ Rebyota and Seres Therapeutics’ Vowst, are expected to further accelerate the integration of microbiome treatments into clinical settings. By harnessing knowledge derived from the expanding research, the microbiome has the potential to offer new avenues for personalized medicine and targeted interventions.
Give your business an edge with our leading industry insights.
